![]() |
市场调查报告书
商品编码
1479962
2024 年全球生技投资成长机会Growth Opportunities in Global Biotech Investment, 2024 |
领先生物製药公司的颠覆性技术和投资组合重组确保了生物技术投资的成长潜力
在这份分析中,Frost & Sullivan 提供了有关生物技术併购和创业投资(VC) 投资的重要见解,确定了生物技术领域的驱动因素、挑战、预测和主要趋势。该分析还确定了行业参与者可以利用的成长机会。
为了了解 2024 年以后的趋势前景,本分析评估了 2019 年至 2023 年的策略和金融投资、併购)、创投和私募股权(PE)。 Frost & Sullivan 收集了整个生态系统的总数。然而,仅分析不涉及小分子资产的生物技术/生物製药交易。本分析的范围是以2023年为基准年的全球,并包含截至2028年的预测。
该评估不包括债务或未决事项。由于资料基于二手信息,因此处理的数量和金额可能会有所不同。同样,生物技术的定义也各不相同。一些资讯来源在公告日期记录併购交易,资讯来源记录交易进度的里程碑,还有资讯来源记录交易结束后的总金额。
Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments
In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.
To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.
This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.